Tirzepatide Side Effects

Gastrointestinal Side Effects

• Tirzepatide commonly causes gastrointestinal side effects including nausea, diarrhea, vomiting, constipation, abdominal pain, and alopecia, with symptoms typically being dose-dependent 1, 2
• Dyspepsia and gastroesophageal reflux can also occur 2
• Management strategies include starting at a low dose and titrating slowly upward, reducing meal size, limiting alcohol and carbonated drinks, avoiding high-fat diets, and avoiding use in patients with gastroparesis 2

Delayed Gastric Emptying and Related Complications

• Tirzepatide delays gastric emptying through GLP-1 receptor activation, which inhibits gastric peristalsis while increasing pyloric tone 3
• Potential complications include risk of ileus, delayed absorption of oral medications, and increased risk of pulmonary aspiration during anesthesia 3

Metabolic and Endocrine Side Effects

• Risk of hypoglycemia increases when tirzepatide is used with insulin or insulin secretagogues 4
• The American Heart Association and other guideline societies warn that tirzepatide can increase the risk of thyroid C-cell tumors and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 5

Cardiovascular Effects

• Increased heart rate may occur, and if cardiac arrhythmia/tachycardia becomes symptomatic, monitoring and consideration of beta blockers may be necessary 2

Hepatobiliary Effects

• Gallbladder disorders can occur but are usually not symptomatic 2

Special Considerations

• In the perioperative period, consideration of tirzepatide administration in relation to surgical procedures requiring general anesthesia is necessary due to delayed gastric emptying 3
• Unlike some other medications in this class, specific dose adjustments for renal function are not prominently mentioned in guidelines for tirzepatide, according to the American Medical Association and the National Kidney Foundation 1, 4
• Healthcare providers should monitor for potential consequences of delayed absorption of oral medications 3

Adverse Effects of Tirzepatide

Cardiovascular Effects

• The American Diabetes Association notes that increased heart rate may occur with tirzepatide, as reported in studies published in Diabetes Care in 2022 and 2021, with a strength of evidence based on clinical trials 6, 7
• Elevated heart rate is a recognized side effect across the GLP-1 receptor agonist class, according to a study published in Circulation in 2019 8

Dermatological and Injection Site Effects

• Injection site reactions may occur, as reported in studies published in Diabetes Care in 2022 and 2023, with a strength of evidence based on clinical trials 6, 9

Hepatobiliary Effects

• The American Association of Clinical Endocrinologists notes that gallbladder disorders, including cholelithiasis and cholecystitis, can occur but are usually asymptomatic, with a rate of ≤1% across all doses, as reported in a study published in Diabetes Care in 2023 9

Side Effects Requiring Discontinuation of Tirzepatide

Absolute Indications for Discontinuation

• The American College of Cardiology recommends immediate and permanent discontinuation of tirzepatide in patients with suspected or confirmed acute pancreatitis, and tirzepatide should not be restarted if pancreatitis is confirmed, due to the risk of severe adverse events 10, 11
• The American College of Cardiology advises that a history of serious hypersensitivity reaction to tirzepatide is an absolute contraindication and requires discontinuation 10
• The American College of Cardiology suggests discontinuing tirzepatide if medullary thyroid carcinoma is diagnosed or suspected, particularly in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) 10

Clinical Context and Monitoring

• The American College of Cardiology recommends that patients with gastroparesis should not receive tirzepatide due to delayed gastric emptying effects, and those with prior gastric surgery, including bariatric surgery, require extreme caution 10
• The American College of Cardiology advises considering discontinuation of tirzepatide before surgical procedures requiring general anesthesia due to increased risk of pulmonary aspiration from delayed gastric emptying 12

Severe Adverse Events

• The American College of Cardiology recommends considering discontinuation of tirzepatide if severe hypoglycemia occurs despite dose reduction of concomitant insulin or sulfonylureas 10